Sana Biotechnology, Inc. $SANA Shares Acquired by Deutsche Bank AG

Key Points

• Deutsche Bank AG has significantly increased its holdings in Sana Biotechnology by 87.9% during Q1, now owning approximately 0.30% of the company's stock valued at $1.12 million.
• Analysts are optimistic about Sana Biotechnology, with a consensus rating of "Buy" and a target price averaging around $8.00, despite the stock's recent performance.
• The company's stock price is currently at $3.58, having a 52-week range between $1.26 and $7.30, and a market capitalization of $851.36 million.

Deutsche Bank AG lifted its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 87.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 666,392 shares of the company's stock after acquiring an additional 311,692 shares during the period. Deutsche Bank AG owned 0.30% of Sana Biotechnology worth $1,120,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. raised its holdings in Sana Biotechnology by 0.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,066,304 shares of the company's stock worth $1,791,000 after purchasing an additional 9,792 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Sana Biotechnology by 60.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 56,298 shares of the company's stock valued at $95,000 after acquiring an additional 21,102 shares during the period. Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of Sana Biotechnology by 52.7% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 289,273 shares of the company's stock valued at $483,000 after acquiring an additional 99,801 shares during the period. Summit X LLC acquired a new stake in shares of Sana Biotechnology in the first quarter valued at approximately $60,000. Finally, CWM LLC boosted its holdings in shares of Sana Biotechnology by 290.7% in the first quarter. CWM LLC now owns 38,431 shares of the company's stock valued at $65,000 after acquiring an additional 28,595 shares during the period. Institutional investors and hedge funds own 88.23% of the company's stock.

Analyst Upgrades and Downgrades

SANA has been the subject of several research analyst reports. JMP Securities reissued a "market outperform" rating and issued a $5.00 price objective on shares of Sana Biotechnology in a report on Tuesday, June 24th. Morgan Stanley began coverage on Sana Biotechnology in a report on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 target price on the stock. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Sana Biotechnology currently has an average rating of "Buy" and an average price target of $8.00.

Sana Biotechnology Trading Up 1.7%

Shares of SANA traded up $0.05 during mid-day trading on Friday, hitting $3.06. The company's stock had a trading volume of 3,260,466 shares, compared to its average volume of 6,303,649. The firm has a 50-day simple moving average of $3.69 and a 200 day simple moving average of $2.71. The firm has a market capitalization of $727.70 million, a P/E ratio of -2.89 and a beta of 1.90. Sana Biotechnology, Inc. has a 1-year low of $1.26 and a 1-year high of $7.30.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. As a group, sell-side analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.